This contract opportunity involves the establishment of non-exclusive discount agreements for the drug Trastuzumab, classified under ATC code L01FD01, in the regions of Lower Saxony, Bremen, and Saxony-Anhalt. The focus is on parenteral preparations made from finished medicinal products for oncology
242 days left to bid. Opened 1 years ago, deadline 21 Apr 2027.
This contract opportunity involves establishing a non-exclusive discount agreement for medications containing the active ingredient Teriparatide (ATC Code: H05AA02). The contract will be effective from December 1, 2025, to November 30, 2027, with the option for suppliers to enter into the contract a
This contract opportunity involves establishing a non-exclusive discount agreement for the medication Omalizumab (ATC Code: R03DX05) in Germany. The contract will be effective from December 1, 2024, to November 30, 2026, with the option for suppliers to enter into the contract at any time during thi
Innovate UK is investing up to £25.4 million to help develop and test early cancer diagnostic technologies, particularly for less common cancers, with projects costing £1.5-£4 million over 24-36 months.
Innovate UK is offering up to £25.4 million to fund collaborative projects that clinically validate innovative early cancer diagnostic technologies and devices led by UK organisations including at least one SME.
UKHSA seeks supplier information for Doxycycline 10-pack supply through a preliminary market engagement exercise under the Procurement Act 2023.
Suppliers are invited to complete a preliminary market engagement questionnaire about patient diagnostic and monitoring electrodes by 21st September 2026 through eTendersNI.
